Endometrial Hyperplasia
Return to Library
|
Free Endometrial Hyperplasia Articles |
|
|
|
|
Studies from Shinshu University, Medical Department further understanding of endometrial hyperplasia
2009 JUN 22 - (NewsRx.com) -- "Although progestins have been used for the treatment of endometrial neoplasias, the mechanisms of progestin-induced growth suppression remain undetermined. Immunostaining for steroid receptor coactivators (SRC-1, p300/CBP), corepressors (NCoR, SMRT) and Ki-67 in 15 neoplastic endometria before and after the treatment with medroxyprogesterone acetate (MPA) was performed," scientists writing in the journal Anticancer Research report. "The effect of progestin on cell proliferation and cofactors expression were examined using T47D cells. Of the 15 cases, 10 showed good histological responses to MPA (Responder) and 5 poor responses (Non-responder). In Responders, MPA treatment resulted in reduced expression of Ki-67 by 78% (p=0.0076) along with increased NCoR expression by 158 % (p=0.0077). Progestin treatment for T47D cells resulted in up-regulation of NCoR mRNA and protein with the suppression of cell proliferation. Immunoprecipitation revealed that NCoR was bound to estrogen receptor a, but not to progesterone receptor in T47D cells," wrote H. Kashima and colleagues, Shinshu University, Medical Department. The researchers concluded: "The up-regulation of NCoR by progestins is associated with the suppression of estrogen-induced growth of neoplastic cells." Kashima and colleagues published their study in Anticancer Research (Up-regulation of Nuclear Receptor Corepressor (NCoR) in Progestin-induced Growth Suppression of Endometrial Hyperplasia and Carcinoma. Anticancer Research, 2009;29(4):1023-1029). Additional information can be obtained by contacting A. Horiuchi, Shinshu University, School Medical, Dept. of Obstetrics & Gynecology, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan. The publisher of the journal Anticancer Research can be contacted at: International Institute Anticancer Research, Editorial Office 1ST km Kapandritiou-Kalamou Rd. Kapandriti, PO Box 22, Athens 19014, Greece. Keywords: Japan, Matsumoto, Anticancer Therapy, Cancer Research, Cell Proliferation, Contraceptive, Drugs, Endometrial Cancer, Endometrial Carcinoma, Endometrial Hyperplasia, Hormone, Medroxyprogesterone Acetate, Neoplasia, Oncology, Pharmaceuticals, Progesterone, Therapy, Treatment, Women's Health, Shinshu University, Medical Department. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
